Cell-based therapies are considered as one of the most promising approaches for the treatment of degenerating pathologies including muscle disorders and dystrophies. Advances in the approach of reprogramming somatic cells into induced pluripotent stem (iPS) cells allow for the possibility of using the patient’s own pluripotent cells to generate specific tissues for autologous transplantation. In addition, patientspecific tissue derivatives have been shown to represent valuable material for disease modeling and drug discovery. Nevertheless, directed differentiation of pluripotent stem cells into a specific lineage is not a trivial task especially in the case of skeletal myogenesis, which is generally poorly recapitulated during the in vitro differentiation of pluripotent stem cells. Here, we describe a practical and efficient method for the derivation of skeletal myogenic precursors from differentiating human pluripotent stem cells using controlled expression of PAX7. Flow cytometry (FACS) purified myogenic precursors can be expanded exponentially and differentiated in vitro into myotubes, enabling researchers to use these cells for disease modeling as well as therapeutic purposes.
|Original language||English (US)|
|Title of host publication||Methods in Molecular Biology|
|Publisher||Humana Press Inc.|
|Number of pages||17|
|State||Published - Jan 1 2016|
|Name||Methods in Molecular Biology|
Bibliographical notePublisher Copyright:
© Springer Science+Business Media New York 2014.
- Cell therapy
- Human embryonic stem (ES) cells
- Human-induced pluripotent stem (iPS) cells
- Muscle differentiation
- Myogenic precursors
- Skeletal muscle